A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29

Br J Pharmacol . 2020 May 1. doi: 10.1111/bph.15094. Online ahead of print. A Rational Roadmap for SARS-CoV-2/COVID-19 Pharmacotherapeutic Research and Development. IUPHAR Review 29 S P H Alexander 1, J Armstrong 2, A P Davenport 3, J Davies 4, E Faccenda 2, S D Harding 5, F Levi-Schaffer 6, J J Maguire 7, A J Pawson 8, C Southan 9, M J Spedding 10

Summary

In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed; an agenda for drug re-purposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methodologies aimed at discovering novel chemical and biological means targetting a short-list of host and viral entities should extend the arsenal of anti-SARS-CoV-2 agents. This longer-term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.

All papers

Our partners

International Eosinophil Society (IES) European Centre for Allergy Research Foundation (ECARF) DFG Priority Programme SPP 1394 “Mast cells” European Academy of Allergy and Clinical Immunology (EAACI) European Competence Network on Mastocytosis (ECNM) European Histamine Research Society (EHRS) European Cooperation in Science and Technology (COST) Global Allergy and Asthma Excellence Network (GA²LEN)

Your help is appreciated!

If you want to support our activities by donation or if you want to become a sponsor of EMBRN, please contact us.